1 / 4

Apixaban Versus Warfarin in Patients with AF and ACS or PCI: The AUGUSTUS Trial

Apixaban Versus Warfarin in Patients with AF and ACS or PCI: The AUGUSTUS Trial. Exclusion Contraindication to DAPT Other reason for warfarin (prosthetic valve, mod/ sev MS). Inclusion AF (prior, persistent, or >6 hrs duration) Physician decision that oral anticoag is indicated

Ava
Download Presentation

Apixaban Versus Warfarin in Patients with AF and ACS or PCI: The AUGUSTUS Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Apixaban Versus Warfarin in Patients with AF and ACS or PCI: The AUGUSTUS Trial Exclusion • Contraindication to DAPT • Other reason for warfarin (prosthetic valve, mod/sev MS) • Inclusion • AF (prior, persistent, or >6 hrs duration) • Physician decision that oral anticoag is indicated • ACS and/or PCI with planned P2Y12 inhibitor for 6 months Randomize n =4,600 Patients Apixaban Warfarin P2Y12 inhibitor for all patients x 6 months Aspirin for all on the day of ACS or PCI Aspirin versus placebo after randomization ASA ASA placebo placebo Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis

  2. The AUGUSTUS Trial • A real-world, logistically easy trial, with reduced SAE reporting, risk based monitoring and minimal in-person visits, with local labs • Study Design • 4600 participants,  650 sites,  30 countries • 2x2 factorial design comparing • Open Label apixaban 5 mg BID vs warfarin (INR 2-3) • Blinded aspirin vs aspirin-placebo

  3. The AUGUSTUS TrialStudy Design Two Primary Hypotheses (2 x 2 factorial) • Apixaban is non-inferior to warfarin on ISTH major or clinically relevant non-major bleeding in patients with AF who develop ACS and/or undergo PCI with planned antiplatelet therapy. • Single antiplatelet therapy with a P2Y12 inhibitor is superior to dual antiplatelet therapy with a P2Y12 inhibitor and aspirin on ISTH major bleeding or clinically relevant non-major bleeding in patients with AF who develop ACS and/or undergo PCI with concomitant antiplatelet therapy.

  4. The AUGUSTUS TrialInclusion / Exclusion Criteria • Inclusion criteria • Age >=18 years with atrial fibrillation/flutter with planned use of oral anticoagulant • ACS event and/or PCI with stent within past 2 weeks • Planned P2Y12 inhibitor use for at least 6 months • Exclusion Criteria • Serum Cr >2.5 mg/dL or CrCl< 30mL/min • Other conditions (e.g. DVT or mechanical valves) that require chronic anticoagulation • History of intracranial bleeding • Known bleeding or known contraindications to anticoagulation • CABG (planned or completed) for index ACS event

More Related